NCT02742727 - CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2018

Conditions

Acute Myeloid LeukemiaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaT-cell Prolymphocytic LeukemiaT-cell Large Granular Lymphocytic LeukemiaPeripheral T-cell Lymphoma, NOSAngioimmunoblastic T-cell LymphomaExtranodal NK/T-cell Lymphoma, Nasal TypeEnteropathy-type Intestinal T-cell LymphomaHepatosplenic T-cell Lymphoma

Interventions

BIOLOGICAL

anti-CD7 CAR-pNK cells

The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.

Trial Locations (1)

215123

RECRUITING

PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou